AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25318111 — intervention group
Group type: COMPARATOR
Intervention: Shorter duration of IV antibiotics (62 hours)
Number of subjects: 142
Study 25318111 — intervention group
Group type: COMPARATOR
Intervention: No VCUG ordered
Number of subjects: 142
Study 25318111 — intervention group
Group type: COMPARATOR
Intervention: Transition to oral antibiotics
Number of subjects: 142
Study 25318111 — intervention group
Group type: COMPARATOR
Intervention: Delayed ordering of VCUG
Number of subjects: 142
Study 22233325 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-in prism treatment
Number of subjects: 29
Study 22233325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no prism)
Number of subjects: 29
Study 19578229 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg single dose (n=91)
Number of subjects: 180
Study 19578229 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 20 mg/kg single dose (n=89)
Number of subjects: 180
Study 18081900 — intervention group
Group type: EXPERIMENTAL
Intervention: OAG patients
Number of subjects: 60
Study 18081900 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 16846418 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioversion using Syncrus heart wires
Number of subjects: 174
Study 16846418 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 174
Study 12806460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artemisinin (various doses for one day)
Number of subjects: 234
Study 12806460 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (30mg daily for 7 days)
Number of subjects: 234
Study 12806460 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (30mg daily for 5 days)
Number of subjects: 234
Study 12806460 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (single dose)
Number of subjects: 234
Study 10746603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide (up to 300 microg/day)
Number of subjects: 24
Study 10746603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8634728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized dexamethasone sodium phosphate
Number of subjects: 55
Study 8634728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2002231 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin base 250 mg b.i.d. for 18 months
Number of subjects: 36
Study 2002231 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 36
Study 6405417 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg) taken at bedtime
Number of subjects: 32
Study 6405417 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 29533717 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (n=25)
Number of subjects: 50
Study 29533717 — intervention group
Group type: COMPARATOR
Intervention: 37% carbamide peroxide (n=25)
Number of subjects: 50
Study 29533717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (35% hydrogen peroxide and 37% carbamide peroxide)
Number of subjects: 50
Study 28030569 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally‐specific education programme (PACE and CDSMP)
Number of subjects: 375
Study 28030569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 375
Study 25270275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin threshold (transfusion at 7 g/dL or less)
Number of subjects: 998
Study 25270275 — intervention group
Group type: COMPARATOR
Intervention: Higher hemoglobin threshold (transfusion at 9 g/dL or less)
Number of subjects: 998
Study 25270275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower hemoglobin threshold
Number of subjects: 998
Study 25270275 — intervention group
Group type: COMPARATOR
Intervention: Higher hemoglobin threshold
Number of subjects: 998
Study 22124771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate catheter locks
Number of subjects: 78
Study 22124771 — intervention group
Group type: COMPARATOR
Intervention: Saline catheter locks
Number of subjects: 78
Study 20623992 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus chemotherapy (intravenous panitumumab 6 mg/kg every 2 weeks)
Number of subjects: 0
Study 20623992 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus oxaliplatin-based chemotherapy (FOLFOX4)
Number of subjects: 0
Study 20623992 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus irinotecan-based chemotherapy (FOLFIRI)
Number of subjects: 0
Study 20623992 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab monotherapy plus best supportive care
Number of subjects: 0
Study 20623992 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 0
Study 19072526 — intervention group
Group type: EXPERIMENTAL
Intervention: Social intervention promoting sexual communication
Number of subjects: 0
Study 19072526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16152826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganshao Capsule (GSC) for 8 weeks
Number of subjects: 27
Study 16152826 — intervention group
Group type: COMPARATOR
Intervention: Ganshao Capsule (GSC) followed by Clomiphene (CC) for ovulation induction
Number of subjects: 27
Study 16152826 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (CC) for ovulation induction after GSC
Number of subjects: 27
Study 14660449 — intervention group
Group type: COMPARATOR
Intervention: Single drop of 2.5% povidone‐iodine ophthalmic solution at birth
Number of subjects: 719
Study 14660449 — intervention group
Group type: EXPERIMENTAL
Intervention: Double drop of 2.5% povidone‐iodine ophthalmic solution (one at birth, one at discharge)
Number of subjects: 719
Study 14660449 — intervention group
Group type: EXPERIMENTAL
Intervention: Double drop group
Number of subjects: 719
Study 10664920 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (4 mg single dose)
Number of subjects: 24
Study 8686956 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (cholesterol lowering intervention)
Number of subjects: 0
Study 8686956 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean segment diameter and minimum obstruction diameter (proposed endpoints for standardization)
Number of subjects: 0
Study 1474075 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary contraction
Number of subjects: 8
Study 1474075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonvoluntary contraction
Number of subjects: 8
Study 3881870 — intervention group
Group type: EXPERIMENTAL
Intervention: TUR plus BCG
Number of subjects: 86
Study 3881870 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 86
Study 31016447 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 300 mg I/ml
Number of subjects: 1024
Study 31016447 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol 350 mg I/ml
Number of subjects: 1024
Study 31016447 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 370 mg I/ml
Number of subjects: 1024
Study 31016447 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400 mg I/ml
Number of subjects: 1024
Study 31016447 — intervention group
Group type: COMPARATOR
Intervention: All contrast media
Number of subjects: 1024
Study 30782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-session group-based intervention
Number of subjects: 60
Study 28366039 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC 1% colloidal oatmeal cream
Number of subjects: 90
Study 28366039 — intervention group
Group type: COMPARATOR
Intervention: Prescription barrier cream
Number of subjects: 90
Study 25626811 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid cooling with an ice pack
Number of subjects: 38
Study 25626811 — intervention group
Group type: COMPARATOR
Intervention: Uncooled eyelids
Number of subjects: 38
Study 22963270 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (twice a week at 30 minutes/session for 8 weeks)
Number of subjects: 70
Study 21788633 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 16
Study 21788633 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 100 mg t.i.d.
Number of subjects: 16
Study 20084934 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanism penetration of traditional Chinese medicine, ultrasonic wave and manipulation
Number of subjects: 80
Study 20084934 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic wave and manipulation
Number of subjects: 80
Study 16400507 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Inventory (QOLI)
Number of subjects: 0
Study 15510875 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect Liner F (PL)
Number of subjects: 100
Study 15510875 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F (PF)
Number of subjects: 100
Study 15510875 — intervention group
Group type: EXPERIMENTAL
Intervention: DC core‐Light cured (DCL)
Number of subjects: 100
Study 15510875 — intervention group
Group type: EXPERIMENTAL
Intervention: DC core‐Chemically cured (DCC)
Number of subjects: 100
Study 15510875 — intervention group
Group type: EXPERIMENTAL
Intervention: Super‐EBA (SE)
Number of subjects: 100
Study 15510875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac (KC)
Number of subjects: 100
Study 11053502 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-methionine intervention diet for 1 week followed by a control diet for 1 week (top quartile group)
Number of subjects: 52
Study 11053502 — intervention group
Group type: EXPERIMENTAL
Intervention: High-methionine intervention diet for 1 week followed by a control diet for 1 week (bottom quartile group)
Number of subjects: 52
Study 11053502 — intervention group
Group type: COMPARATOR
Intervention: Control diet (for both groups)
Number of subjects: 52
Study 9248984 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 200
Study 9248984 — intervention group
Group type: COMPARATOR
Intervention: Open hernia repair
Number of subjects: 200
Study 8390288 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐111‐labelled Mab F6 F(ab')2 fragments
Number of subjects: 21
Study 8390288 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc‐99m‐labelled BW 431/26 intact antibody
Number of subjects: 21
Study 8390288 — intervention group
Group type: COMPARATOR
Intervention: Normal serum CEA
Number of subjects: 21
Study 8390288 — intervention group
Group type: COMPARATOR
Intervention: Abnormally elevated serum CEA
Number of subjects: 21
Study 3621821 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ionic medium (meglumine iothalamate)
Number of subjects: 0
Study 3621821 — intervention group
Group type: COMPARATOR
Intervention: Low osmolar medium (sodium meglumine ioxaglate)
Number of subjects: 0
Study 29748010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + pelareorep (4.5 × 10^10 TCID50, days 1-3 every 21 days)
Number of subjects: 166
Study 29748010 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (pemetrexed [500 mg/m2, non-squamous] or docetaxel [75 mg/m2], day 1 every 21 days)
Number of subjects: 166
Study 27240903 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161
Study 27240903 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161
Study 27240903 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 or 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161
Study 27240903 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of sofosbuvir (400 mg), velpatasvir (100 mg), and GS‐9857 (100 mg)
Number of subjects: 161
Study 24966134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (school-community program)
Number of subjects: 614
Study 24966134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention non-completers
Number of subjects: 614
Study 24966134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention completers
Number of subjects: 614
Study 24966134 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 614
Study 22293092 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program targeting the opening of intervertebral foramen
Number of subjects: 36
Study 22293092 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 36
Study 19941345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Sensory Index (CSI)
Number of subjects: 272
Study 19941345 — intervention group
Group type: EXPERIMENTAL
Intervention: CSI of 2.5-4.6
Number of subjects: 272
Study 19941345 — intervention group
Group type: EXPERIMENTAL
Intervention: Median compound muscle action potential (CMAP) amplitude and median motor latency
Number of subjects: 272
Study 18285606 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted anticancer agents (various agents, specific dosages and durations not provided)
Number of subjects: 89
Study 15678039 — intervention group
Group type: COMPARATOR
Intervention: Peak creatine kinase MB level < 25 ng/mL
Number of subjects: 800
Study 15678039 — intervention group
Group type: COMPARATOR
Intervention: Peak creatine kinase MB level ≥ 100 ng/mL
Number of subjects: 800
Study 14654628 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study 14654628 — intervention group
Group type: COMPARATOR
Intervention: RSV-IGIV
Number of subjects: 0
Study 10385364 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy with immunotherapy in patients with high IAP levels (>580 microg/ml)
Number of subjects: 253
Study 10385364 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservation of the spleen with immunotherapy in patients with lower IAP values
Number of subjects: 253
Study 9038461 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw thrust as a clinical test for depth of anaesthesia
Number of subjects: 60
Study 9038461 — intervention group
Group type: COMPARATOR
Intervention: Loss of verbal contact
Number of subjects: 60
Study 9038461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for loss of verbal contact
Number of subjects: 60
Study 9038461 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for loss of response to jaw thrust
Number of subjects: 60
Study 9038461 — intervention group
Group type: COMPARATOR
Intervention: Jaw thrust vs loss of verbal contact
Number of subjects: 60
Study 1633275 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with the right hand
Number of subjects: 48
Study 1633275 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 48
Study 6175254 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release pseudoephedrine (SUDAFED S.A.)
Number of subjects: 0
Study 6175254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31907388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower age of first sexual intercourse (AFS)
Number of subjects: 10481
Study 31907388 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cognition genetic variants
Number of subjects: 10481
Study 31907388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle features
Number of subjects: 10481
Study 31907388 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombotic conditions
Number of subjects: 10481
Study 30787634 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone (T20)
Number of subjects: 80
Study 30787634 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone (T40)
Number of subjects: 80
Study 30787634 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylprednisolone (M20)
Number of subjects: 80
Study 30787634 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone (M40)
Number of subjects: 80
Study 28450312 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX+pred
Number of subjects: 218
Study 28450312 — intervention group
Group type: COMPARATOR
Intervention: MTX+plac
Number of subjects: 218
Study 26573086 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study 25205408 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine before trocar site incision and intraperitoneal levobupivacaine immediately after pneumoperitoneum (Group BS)
Number of subjects: 66
Study 25205408 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal levobupivacaine before trocars were withdrawn and incisional levobupivacaine at the end of surgery (Group AS)
Number of subjects: 66
Study 25205408 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 66
Study 18222357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy
Number of subjects: 3090
Study 18222357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study 15198767 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle excision of the transformation zone (NETZ)
Number of subjects: 404
Study 15198767 — intervention group
Group type: COMPARATOR
Intervention: Loop excision (LLETZ)
Number of subjects: 404
Study 11878090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (balneological care)
Number of subjects: 20
Study 9160697 — intervention group
Group type: COMPARATOR
Intervention: CSP only
Number of subjects: 104
Study 9160697 — intervention group
Group type: EXPERIMENTAL
Intervention: CSP plus MP
Number of subjects: 104
Study 7970954 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (Group A, 6 units)
Number of subjects: 102
Study 7970954 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (Group B, 13 units)
Number of subjects: 102
Study 7970954 — intervention group
Group type: EXPERIMENTAL
Intervention: HAV vaccine (Group C, 25 units)
Number of subjects: 102
Study 3313257 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline treatment
Number of subjects: 32
Study 3313257 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study 11563435 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication treatment for pathologic gambling disorder (PGD) in geriatric patients
Number of subjects: 73
Study 11563435 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacologic treatment
Number of subjects: 73
Study 30605260 — intervention group
Group type: EXPERIMENTAL
Intervention: Plazomicin 15 mg/kg
Number of subjects: 16
Study 30248987 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (25 g of crude protein)
Number of subjects: 6
Study 30248987 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (25 g of crude protein)
Number of subjects: 6
Study 30248987 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect protein isolate (25 g of crude protein)
Number of subjects: 6
Study 30248987 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 6
Study 25965008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) at the time of primary cutaneous tumor resection or at secondary wide local excision
Number of subjects: 57
Study 25965008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB)
Number of subjects: 57
Study 24824991 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment using the Lidcombe Program
Number of subjects: 54
Study 24824991 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment using the Lidcombe Program
Number of subjects: 54
Study 22258267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liquid and perceived gastric liquid preloads
Number of subjects: 52
Study 22258267 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived gastric liquid preloads
Number of subjects: 52
Study 20831826 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory prediction configural frequency analysis (CFA) on one-half of the sample (n = 1969)
Number of subjects: 3883
Study 20831826 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory prediction CFA on the second half (n = 1914)
Number of subjects: 3883
Study 20831826 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive role preference
Number of subjects: 3883
Study 20831826 — intervention group
Group type: EXPERIMENTAL
Intervention: Active role preference
Number of subjects: 3883
Study 17632215 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 123
Study 17632215 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (200-800 mg/d)
Number of subjects: 123
Study 17632215 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 123
Study 17632215 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 123
Study 15642062 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized 0.454% stannous fluoride/sodium hexametaphosphate dentifrice
Number of subjects: 143
Study 15642062 — intervention group
Group type: COMPARATOR
Intervention: Negative control dentifrice
Number of subjects: 143
Study 12392239 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep acupuncture treatment
Number of subjects: 58
Study 12392239 — intervention group
Group type: COMPARATOR
Intervention: Superficial (placebo) acupuncture treatment
Number of subjects: 58
Study 12392239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (deep and superficial acupuncture)
Number of subjects: 58
Study 9893072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fracture group
Number of subjects: 32
Study 9893072 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 7482020 — intervention group
Group type: EXPERIMENTAL
Intervention: Harrington rods
Number of subjects: 67
Study 7482020 — intervention group
Group type: EXPERIMENTAL
Intervention: AO internal fixator
Number of subjects: 67
Study 7482020 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior segmental fixator
Number of subjects: 67
Study 2268811 — intervention group
Group type: EXPERIMENTAL
Intervention: Four doses of cefazolin
Number of subjects: 312
Study 2268811 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of cefazolin and three doses of placebo
Number of subjects: 312
Study 2268811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four doses)
Number of subjects: 312
Study 7000475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1.6 g/day)
Number of subjects: 34